Oxford BioMedica (OXB) is a specialist advanced therapy lentivirus-based vector biopharma company. It offers vector manufacturing and development services and is developing its own proprietary drug candidates. In addition to LentiVector® service contracts, OXB will receive royalties on commercial therapies developed with its platform. This deal structure was established with Novartis for KymriahPPPTMPP, the first approved CAR-T therapy, and has now been followed by a collaboration and licence agreement adopting a similar structure with Bioverativ Inc (BIVV), for the development and potential clinical supply of vector to treat haemophilia.
If you'd like to be introduced to the team at Oxford BioMedica, get in touch.Request a meeting